Themis Medicare Ltd Falls to 52-Week Low Amid Continued Downtrend

Stock Performance and Market Context

On 9 March 2026, Themis Medicare Ltd’s share price touched an intraday low of Rs.73.79, representing a 6.65% drop on the day and a 3.59% decline at close. This marks the lowest price level for the stock in the past year, down sharply from its 52-week high of Rs.179.25. The stock has been on a consistent downtrend, falling for six consecutive trading sessions and delivering a cumulative return of -12.46% over this period.

Themis Medicare’s performance today notably lagged behind the Pharmaceuticals & Biotechnology sector, underperforming by 2.46%. The broader market context was also challenging, with the Sensex opening gap down at 77,056.75, down 2.36% from the previous close, and continuing a three-week losing streak with a cumulative decline of 6.93%. The Sensex is currently trading below its 50-day moving average, although the 50-day average remains above the 200-day average, indicating some underlying market resilience despite recent weakness.

Technical Indicators Highlight Bearish Momentum

Themis Medicare is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning underscores the prevailing bearish momentum and suggests that the stock is facing sustained selling pressure. The breach of these moving averages often signals a lack of near-term buying interest and can act as resistance levels in any potential recovery attempts.

Financial Performance and Profitability Trends

Themis Medicare’s financial metrics reveal a challenging environment for growth and profitability. Over the last five years, the company’s operating profit has declined at an annualised rate of -185.54%, indicating a significant contraction in core earnings capacity. The latest half-year results show a net profit after tax (PAT) of Rs.7.32 crore, which has decreased by 50.60% compared to the previous period. Net sales for the same period stood at Rs.168.12 crore, down 20.25%, reflecting subdued revenue generation.

The company’s return on capital employed (ROCE) for the half-year is negative at -3.47%, signalling inefficiencies in capital utilisation and a lack of value creation for shareholders. Additionally, Themis Medicare’s earnings before interest, taxes, depreciation and amortisation (EBITDA) remain in negative territory, which adds to concerns about the company’s ability to generate sustainable cash flows from operations.

Valuation and Market Sentiment

The stock’s current valuation is considered risky relative to its historical averages. Over the past year, Themis Medicare has delivered a total return of -54.43%, substantially underperforming the Sensex, which has gained 3.71% over the same period. This underperformance extends to longer time frames as well, with the stock lagging the BSE500 index over the last three years, one year, and three months.

Market participants appear cautious, as evidenced by the absence of domestic mutual fund holdings in the company. Despite the company’s size, domestic mutual funds hold 0% stake, which may reflect limited confidence in the stock’s prospects or concerns about the underlying business fundamentals.

Debt and Liquidity Position

On a positive note, Themis Medicare maintains a relatively low debt burden with a Debt to EBITDA ratio of 0.86 times. This indicates a manageable level of leverage and a reasonable capacity to service debt obligations. The company’s ability to meet its financial commitments may provide some stability amid the broader challenges faced by its operations and market valuation.

Mojo Score and Rating Update

Themis Medicare currently holds a Mojo Score of 26.0, categorised as a Strong Sell. This rating was upgraded from a Sell grade on 1 February 2025, reflecting a deterioration in the company’s overall quality and outlook. The Market Cap Grade stands at 4, indicating a relatively modest market capitalisation within its sector. These scores encapsulate the company’s recent financial performance, valuation concerns, and market positioning.

Summary of Key Metrics

To summarise, Themis Medicare Ltd’s key performance indicators as of 9 March 2026 are:

• New 52-week low price: Rs.73.79
• One-year stock return: -54.43%
• Operating profit annualised decline (5 years): -185.54%
• Latest half-year PAT: Rs.7.32 crore (-50.60%)
• Latest half-year net sales: Rs.168.12 crore (-20.25%)
• ROCE (half-year): -3.47%
• Debt to EBITDA ratio: 0.86 times
• Mojo Score: 26.0 (Strong Sell)

The stock’s recent price action and financial results highlight the challenges faced by Themis Medicare in maintaining growth and profitability. The sustained decline to a 52-week low reflects these underlying issues and the cautious stance adopted by market participants.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →